ADJUVANTS IN MODERN MEDICINE AND VETERINARY

  • Authors: Kozlov V.G1, Ozherelkov S.V2, Sanin A.V3, Kozhevnikova T.N3
  • Affiliations:
    1. Enterprise for Production of Bacterial and Virus Preparations of Chumakov Research Institute of Poliomyelitis and Viral Encephalitis, Moscow Region, Russia
    2. Chumakov Research Institute of Poliomyelitis and Viral Encephalitis, Moscow Region, Russia
    3. Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia
  • Issue: Vol 91, No 1 (2014)
  • Pages: 91-102
  • Section: Articles
  • URL: https://microbiol.crie.ru/jour/article/view/13930
  • ID: 13930

Cite item

Full Text

Abstract

The review is dedicated to immunologic adjuvants - various natural and synthetics substances that are added to vaccines for stimulation of specific immune response, but they do not induce specific response themselves. Critically important is the selection of the correct adjuvants, for which mechanisms of effect on immune system are studied the most. The majority of these mechanisms as well as physical-chemical and biological features of modern adjuvants are analyzed in the review. The problem of safety of adjuvants, types of immune response induced by adjuvants of various nature, excipients that are being verified or already in use in modern medicine and veterinary are also examined.

About the authors

V. G Kozlov

Enterprise for Production of Bacterial and Virus Preparations of Chumakov Research Institute of Poliomyelitis and Viral Encephalitis, Moscow Region, Russia

S. V Ozherelkov

Chumakov Research Institute of Poliomyelitis and Viral Encephalitis, Moscow Region, Russia

A. V Sanin

Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia

T. N Kozhevnikova

Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia

References

  1. Медуницын Н.В., Покровский В.И. Основы иммунопрофилактики и иммунотерапии инфекционных болезней. Руководство для врачей. Гэотар-Медиа, 2005.
  2. Хаитов Р.М., Пинегин Б.В. Основные принципы иммуномодулирующей терапии. Аллергия, астма и клиническая иммунология. 2000, 1: 9-16.
  3. Ярилин А. А. Цитокинотерапия. Аллергия, астма и клиническая иммунология. 2000, 1: 30-31.
  4. Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today. 1993, 14: 281-284.
  5. Audibert F.M., Leclerc C., Chedid L. Muramyl peptides as immunopharmolocological response modifiers. In: Biological response moodifiers. New approaches to disease prevention. P.F. Torrence (ed.). Orlando, Academic Press. 1985: 307-327.
  6. Aucouturier J., Ascarateil S. The use of oil adjuvantes in therapeutic vaccines. Vaccine. 2006, 24: 44-45.
  7. Allison A.C., Byars N.E. Syntex adjuvant formulation. Res. Immunol. 1992, 143: 519-525.
  8. Alving C.R. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophis. Acta Rev. Biomembr. 1992, 1113: 307322.
  9. Altman A., Dixon FJ. Immunomodifiers in vaccines. Adv. Vet. Sci. Comp. Med. 1989, 33: 301-343.
  10. Brewer J.M., Conacher M., Satoskar A. In interleukin-4-deficient mice, alum not only generates T helper I responses equivalent to Freund’s complete adjuvant, but continues to induce T helper 2 cytokine production. Eur. J. Immunol. 1996, 26: 2062-2066.
  11. Byars N.E., Allison A.C. Immunologic adjuvants: general properties, advantages, and limitations. In: Laboratory methods in immunology. H. Zola (ed.). 1990: 39-51.
  12. Brodersson J.R. A retrospective review of lesions associated with the use of Freund’s adjuvant. Lab. Anim. Sci. 1989, 39: 400-405.
  13. Byars N.E., Allison A.C., Harmon N.W., Kendal A. Enhancement of antibody responses to influenza B virus haemagglutinin by use of new adjuvant. Vaccine. 1990, 8: 49-56.
  14. CCAC (Canadian Council on Animal Care) CCAC Guidelines on antibody production, Ottawa ON: CCAC.2002.
  15. Cohen I.R. Adjuvant arthritis. In: Encyclopedia of Immunology. I.M. Roitt, PJ. Delves (ed.). San Diego, Academic Press. 1992: 26-28.
  16. Edelman R. The development and use of vaccine adjuvants. Mol. Biotechnol. 2002, 21: 129148.
  17. Ennis F.A., Cruz J., Jameson J.et al. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology.1999, 259: 256-261.
  18. Gregoriadis G., Panagiotidi C. Immunoadjuvant action of liposomes; comparisonitch other adjuvants. Immun. Lett. 1989, 20: 237-240.
  19. Hughes H.P.A., Babiuk L.A. Potentiation of vaccines through effective Adjuvant formulations and manipulations of the immune response. In: Modern vaccinology. E. Kurstak (ed.). New-York, Plenum Publisching Corporation, 1994: 87-118.
  20. Hanly W.C. et al. Adjuvants and antibody production. Rewiew of Polyclonal Antubody Production Procedures in Mammals and Poultry. ILAR J. 1995: 37.
  21. Henricson D.A., Benjamin W.R., Vogel S.N. Differential cytokine induction by doses of li-popolysaccharide and monophosphoril lipid A that result in equivalent early endotoxin tolerance. Infect. Immun. 1990, 58: 2429-2437.
  22. Hunter R.L., Bennett B. The adjuvant activity of nonionic block polymer surfactants: II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 1984, 133: 167-3175.
  23. Howerton D.A., Hunter R.L., Zigler H.K., Check I.J. Induction of macrophage Ia expression in vivo by a synthetic block copolimer, L81. 1990, 144: 1578-1584.
  24. Jones G.L. Peptide vaccine derived from a malarial surface antigen: effect of dose and adjuvant on immunogenicity. Immunol. Lett. 1990, 24: 253-260.
  25. Jiang W, Swiggard WJ., Heufler WJ. et al. The receptor DEC-205 expressed by dendritic cells and thymic epitelial cells is involved in antigen processing. Nature. 1995, 375: 151-155.
  26. Kotani S. Bacterial cell surface biological responce modifiers and their synthetic counterparts. In: Advances in experimental i^diane and biology. H. Friedman, T.W Klein, H. Jamaguchi (ed.). New-York, Plenum Press, 1992, 319: 145-164.
  27. Kimura J., Nariuchi H., Watanabe T. et al. Studies on the adjuvant effect of water-in-oil-in water emulsion in sesame oil. I. Enhanced and persistent antibody formation by antigen incorporated into the water-in-oil-in-water emulsion. Jpn. J. Exp. Med. 1978, 48: 149-152.
  28. Kenney R.T., Edelman R. Survey of human-use adjuvants. Expert Rev.Vaccines. 2003, 2: 167188.
  29. Kotani S. et al. Immunobiological activities of synthetic lipid A analogs with low endotoxicity. Infect. Immun. 1986, 54: 673-682.
  30. Lindblad E. B. Aluminium adjuvants. In: Theory and practical application of adjuvants. D.T.S. Stewart-Tull (ed.). New-York, John Wiley and Sons, 1995: 21.
  31. Lemaire G. Natural and synthetic trehalose diesters as immunomodulators. Med. Res. Rev. 1986, 6: 243.
  32. Lipman N.S., Trudel L.J., Murphy J.C., Sahali Y. Comparison of immune response potentiation and in vivo inflammatory effects of Freund’s and Ribi adjuvants in mice. Lab. Anim. Sci. 1992, 42: 193-197.
  33. McCoy K.L, Kendrick L., Chused T.M. Tolerance defects in New Zealand Black and New Zealand Black and New Zealand White F1 mice. J. Immunol. 1986, 136: 1217-1222.
  34. McKee A., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007, 27: 687-690.
  35. Mastrangelo J., Berd D. Immunotherapy with microbial products. In: Immunological approaches to cancer therapeutics. E. Mihich (ed.). New-Yark, Wiley, 1982: 11.
  36. Osebold J.W. Mechanism of action by immunologic adjuvants. J.Am.Vet.Med.Assoc. 1982, 181: 983-987.
  37. Parant M.A., Audibert F.M., Chedid L. Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of a desmuramyl peptidolipid analogue. Infect. Immun. 1980, 27: 826-830.
  38. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends in Immunol. 2008, 30: 23-32.
  39. Ronnberg B., Fekadu M., Morein B. Adjuvant activity of non toxic Quillaja saponaria Molina components for use in iscom-matrix. Vaccine.1995, 13: 1375-1382.
  40. Ribi E.T., Meyer J., Azuma I. et al. Biologically active components from micobacterial cell walls. IV. Protection of mice against aerosol infection with virulent Mycobacterium tuberculosis. Cell. Immunol. 1975, 16: 1-10.
  41. Stewart-Tull D.E.S. Harmful and beneficial activities ofimmunological adjuvants. In: Methods in molecular medicine: vaccine adjuvants-preparation methods and research protocols. D.T O’Hagen (ed.). Human Press, 2000: 29-48.
  42. Seubert A., Monaci T., Pizza M. et al. The adjuvants aluminium hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J.Immunol. 2008, 180: 5402-5412.
  43. Souberbielle B.E., Knight B.C., Morrow WJ.W et al. Comparison of IL-2 and IL-4-transfec-ted B16-F-10 cells with a novel oilmicroemulsion adjuvant for B16-F-10 whole cell tumor vaccine. Gene Ther. 1996, 3: 853-885.
  44. Scalzo A.A. et al. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J. Virol. 1995, 69: 1306-1309.
  45. Singh M., O’Hagan D. Advances in vaccine adjuvants. Nat.Biotechnol. 1999, 17: 10751081.
  46. Tomai M.A., Johnson A.G. T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. J. Biol. Resp. Modifiers. 1989, 8: 625-630.
  47. Takada H., Kotani S. Structural requirements of lipid A for endotoxicity and other biological activities. Crit. Rev. Microbiol. 1989, 16: 477-523.
  48. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 2001, 69: 1151-1159.
  49. Vogel F.R. Adjuvants in perspective. In: Modification of the immune response to vaccine antigens. F. Brown, L.Haaheim (ed.). Dev. Biol. Stand. Basel, Karger,1998: 241-248.
  50. Vogel F.R. Improving vaccine performance with adjuvants. Clin. Inf. Dis. 2000, 30 (l3): 266270.
  51. Warren H.S., Chedid L.A. Future prospects for vaccine adjuvants. CRC Crit. Rev. Immunol. 1986, 4: 369-388.
  52. Woodard L.F. Surface chemistry and classification ofvaccineadjuvants and vehicles. In: Bacterial vaccines. A. Mizrahi (ed.). New York, 1990: 286-306.
  53. Weibel R.E., McLean A., Woodhour A.F. et al. Ten-year follow-up study for safety of adjuvant 65 influenza vaccine in man. Proc. Soc. Exp. Biol. Med. 1973, 143: 1053-1056.
  54. Waksman B.H. Adjuvants and immune regulation by lymphoid cells. Springer Semin. Immunopathol.1979, 2: 5-9.
  55. Whistler R.L. Noncytotoxic antitumor polisaccharides. Adv. Carbohydro. Chem. Biohem. 1976, 32: 235-241.
  56. White A.C., Cloutier P., Coughlin R.T. et al. A purified saponin acts as an adjuvant for a T-independent antigen. Adv. Exp. Med. Biol. 1991, 303: 207-210
  57. Weiner G.J., Hsin-Ming Liu, Wooldridge J.F. et al. Immunostimulatory oligodeoxynucletides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. 1997, 94: 10833-10837.
  58. Woodard L.F., Jasman R. Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants. Vaccine. 1985, 3: 57-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Kozlov V.G., Ozherelkov S.V., Sanin A.V., Kozhevnikova T.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies